2024 Peace-1 vs arasens

Peace-1 vs arasens

Author: ibwx

August undefined, 2024

SpletIn ARASENS, darolutamide (DARO) + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death by 32.5% vs placebo (PBO) + ADT + docetaxel (HR 0.68, 95% CI 0.57–0.80) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Given the potentially long treatment duration, the impact of DARO + ADT + … Splet01. mar. 2024 · The ARASENS results suggest darolutamide plus ADT and docetaxel can be considered a standard of care option for mHSPC. ... (7.8% vs 7.4%), hypertension (6.4% vs 3.2%), anemia (4.8% vs 5.1%), and pneumonia (3.2% vs 3.1%). Dr. Smith noted that many of the grade 3/4 AEs were attributable to docetaxel. After adjusting for treatment exposure, …

How Does the Data from the PEACE-1, ARASENS and ENZAMET

Splet25. feb. 2024 · The reason I say that is because you had mentioned the PEACE-1 study data, which just came out at ESMO [European Society for Medical Oncology Annual Meeting]. … Splet24. mar. 2024 · To the Editor: The results of the ARASENS trial (March 24 issue) 1 represent the beginning of the third revolution in the treatment of metastatic hormone-sensitive … expertbook wallpaper

PEACE-1試験：最近話題のキーワード：日経メディカル Online

SpletRecent results from both the PEACE-1 and ARASENS trials show an overall survival and progression-free survival benefit from the addition of an androgen-receptor pathway inhibitor for patients in whom the SOC option of ADT plus docetaxel has been chosen in de novo metastatic hormone-sensitive prostate cancer, Splet08. mar. 2024 · However, the results of phase III trials investigating the addition of other AR inhibitors to ADT and docetaxel in this setting are conflicting: in PEACE-1, abiraterone was associated with an OS... Splet11. jan. 2024 · Notably, the PEACE-1 study was exclusively a trial for patients with synchronous mHSPC, and ARASENS enrolled predominantly (86%) synchronous patients, … btw means texting

Is Triple Therapy the New Standard for Metastatic Hormone …

Cancers Free Full-Text Systemic Triple Therapy in Metastatic

Splet11. nov. 2024 · A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first... Splet01. jan. 2024 · Both PEACE-1 and ARASENS demonstrated an OS benefit of triplet therapy over doublet therapy compared with doublet therapy [14], [15]. It is of note that both PEACE-1 and ARASENS relied on docetaxel with ADT (doublet therapy) as a control arm in contrast to previous RCTs. btw. meaningSplet21. mar. 2024 · As Chris alluded to in the introduction, these results are in line with a PEACE-1 trial, which was presented recently, but not yet published where 1,173 men with metastatic hormone-sensitive prostate cancer, randomized to abiraterone versus prostate radiotherapy versus abiraterone plus radiotherapy versus neither with all patients … btw means text message

"Splet3 or 4 adverse events was 66.1% in the darolutamide group and 63.5% in the pla- cebo group; neutropenia was the most common grade 3 or 4 adverse event (in 33.7% and 34.2%, respectively). " - Peace-1 vs arasens

Peace-1 vs arasens

ASCO 2024: First Results of PEACE-1: A Phase 3 Trial with a ... - UroTod…

SpletFrom a subgroup analysis of the PEACE-1 trial, which was presented by Dr Karim Fizazi at the 2024 European Society for Medical Oncology (ESMO) Congress and recently published, we learned that the addition of abiraterone to ADT/docetaxel improves OS in patients with high-volume disease. SpletSubsequently, in data presented at ASCO and ESMO, the PEACE-1 trial demonstrated that there may be additional benefit from combined triplet treatment intensification with …

Did you know?

Splet31. maj 2024 · The so-called PEACE-1 trial is an ongoing Phase III trial among men diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC). The earliest results of this trial are to be presented by Fizazi et al. at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO). SpletSo, in PEACE-1, I think it's important to remember that at the moment, the benefit of triplet therapy in low-volume disease has not really been demonstrated, and that the median …

Splet26. feb. 2024 · In phase 1/2 ARADES and phase 1 ARAFOR trials, darolutamide demonstrated antitumor activity and was well tolerated in men with metastatic castration … Splet21. dec. 2024 · Regarding intensified AR targeting, one of the most promising trials is the ARASENS study. This phase III study will consist of approximately 1300 mHSPC patients who will be randomized in a 1:1 ratio to receive 1200 mg/daily of the second-generation antiandrogen darolutamide daily compared to control, each in addition to standard ADT …

Splet01. sep. 2024 · In contrast, the PEACE-1 and ARASENS trials prospectively enrolled patients treated with ADT and docetaxel in the majority or all cases, respectively. These two groundbreaking trials suggest that there is a significant OS benefit with the addition of an ARSi to docetaxel and ADT upfront in most patients with mCSPC [16, 17]. Both of these … Splet21. feb. 2024 · PEACE-1 verglich ADT + Abirateron + Docetaxel vs. ADT + Docetaxel und zeigte einen Benefit in der radiologischen ... 95% CI: 0,40–0,62; p<0,0001) und bei „Highvolume“-Tumoren eine Verlängerung des OS. 2 In der ARASENS-Studie, die ADT + Darolutamid + Docetaxel vs. ADT + Docetaxel bei de novo Rezidivpatienten untersuchte, …

Splet10. feb. 2024 · Die Hypertension zeigt auch hier in der ARASENS-Studie eine der häufigsten Nebenwirkungen v. a. in der Triplet-Therapiegruppe, allerdings mit deutlich geringer Inzidenz als in der PEACE-1-Studie mit 6,4 vs. 3,2 %.

Splet17. jun. 2024 · ARASENS和PEACE-1试验表明，在多西他赛+雄激素剥夺疗法（ADT）中加入NHT可改善mCSPC的总体生存率（OS），然而，目前尚缺乏对其中多西他赛的有效性研究评估，本次荟萃分析将评估mCSPC联合方案中多西他赛对生存结果的影响。从PubMed和Embase数据库进行文献检索，共检索到2565条记录。筛选可用记录后，纳入了6项三期 … expert bornaSplet01. mar. 2024 · In the ARAMIS study, the median metastasis-free survival was almost 2 years longer and the risk of death was 31% lower among patients who received darolutamide with ADT than among those who received placebo with ADT, and the incidence of adverse events was similar in the two groups. btw means shortSplet25. feb. 2024 · Findings from ARASENS are consistent with the PEACE-1 (NCT01957436) trial. PEACE-1, a phase 3 study for patients with metastatic hormone-naïve prostate … expertbook r11 br1100fSplet21. jul. 2024 · The PEACE-1 and ARASENS trials have both shown an OS and PFS benefit from the addition of an androgen-receptor pathway inhibitor to the SOC option of ADT … btw means whatSplet20. sep. 2024 · medwireNews: The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy (ADT) significantly improves the overall survival (OS) of patients with de novo metastatic castration-sensitive prostate cancer (mCSPC), report the PEACE-1 investigators.. Speaking at the ESMO Congress 2024, … btw meanSpletキーワード別記事一覧：PEACE-1試験 de novoの転移を有するCSPCでADT＋ドセタキセルへのアビラテロンの追加により死亡のリスクが25％低下【ESMO 2024】 de... expert bornemSplet10. jun. 2024 · 在peace-1研究的初步结果中，单纯去势治疗加多西他赛的pfs约为24个月，虽然不能直接比较，但是接近chaarteed研究中治疗组的27.3个月，在此基础上，再联用阿比特龙，能额外增加2.5年的中位pfs，体现了阿比特龙的额外生存优势，而且无明显的额外短期毒性，只是在 ... expert bootmakers perth